Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Clavulanic Acid in the Scope of Helicobacter pylori Treatment: A Literature Review and Beyond

Author(s): Nasr Alrabadi*, Iyad S. Albustami, Husam A. Abuhayyeh, Khaled M. El-Muwalla, Rama J. Alawneh, Laith N. AL-Eitan, Karem H. Alzoubi, Majed Masadeh, Omar F. Khabour and Razan Haddad

Volume 16, Issue 2, 2021

Published on: 02 July, 2020

Page: [128 - 138] Pages: 11

DOI: 10.2174/1574884715666200702121417

Price: $65

Abstract

Background: Helicobacter pylori (H. pylori) infection is the most common cause of peptic ulcer disease and it can be associated with many complications, including malignancies. In clinical practice, some clinicians may use Clavulanic Acid (CA) in combination with amoxicillin or other beta-lactams as an addition to the standard treatment regimens. This practice may be done by habitual mistake, non-evidence based hypothetical assumptions, or by prescribing it as an alternative treatment. This review aims to expose the effect of CA against H. pylori infection and to review the possible mechanisms that may contribute to that effect.

Methods: A PubMed and Google Scholar literature search was obtained on both pre-clinical and clinical studies related to CA and H. pylori infection.

Results: Available clinical studies showed improvement in the eradication of H. pylori by about 10- 20% when CA was added to the treatment regimens. This effect for CA could be related to several mechanisms including inhibition of H. pylori growth by binding to Penicillin-Binding Proteins (PBPs), the transformation of H. pylori from the active filamentous form into coccoidal form, induction of the release of dopamine, modulation of immunological response towards H. pylori infection and its relationship with other microbiota. Randomized-controlled studies on patients with resistance to H. pylori are needed. Moreover, in vitro studies to evaluate the mechanisms by which CA may influence H. pylori are warranted.

Conclusion: The presented literature suggests potential avenues for the use of CA in the management of peptic ulcer disease and H. pylori infection.

Keywords: Clavulanic acid, clauvanate, Helicobacter pylori, eradication therapy, peptic ulcer disease, gastric cancer.

« Previous Next »
Graphical Abstract

[1]
Nagarajan R, Boeck LD, Gorman M, et al. Beta-lactam antibiotics from Streptomyces. J Am Chem Soc 1971; 93(9): 2308-10.
[http://dx.doi.org/10.1021/ja00738a035] [PMID: 5553073]
[2]
Severin A, Severina E, Tomasz A. Abnormal physiological properties and altered cell wall composition in Streptococcus pneumoniae grown in the presence of clavulanic acid. Antimicrob Agents Chemother 1997; 41(3): 504-10.
[http://dx.doi.org/10.1128/AAC.41.3.504] [PMID: 9055983]
[3]
Reading C, Cole M. Clavulanic acid: A beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11(5): 852-7.
[http://dx.doi.org/10.1128/AAC.11.5.852] [PMID: 879738]
[4]
Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB. Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. Neurosci Lett 2011; 504(2): 170-5.
[http://dx.doi.org/10.1016/j.neulet.2011.09.032] [PMID: 21964384]
[5]
Finlay J, Miller L, Poupard JA. A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother 2003; 52(1): 18-23.
[http://dx.doi.org/10.1093/jac/dkg286] [PMID: 12775671]
[6]
Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017; 153(2): 420-9.
[http://dx.doi.org/10.1053/j.gastro.2017.04.022] [PMID: 28456631]
[7]
Biological agents. A review of human carcinogens IARC Monogr Eval Carcinog Risks Hum 2012; 100 B(Pt B): 1-441.
[8]
WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization. Available at: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
[9]
Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized, double-blind trial. Am J Gastroenterol 1993; 88(11): 1860-4.
[PMID: 8237933]
[10]
Salcedo JA, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med 1998; 158(8): 842-51.
[http://dx.doi.org/10.1001/archinte.158.8.842] [PMID: 9570169]
[11]
Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I Study. Helicobacter 1996; 1(3): 138-44.
[http://dx.doi.org/10.1111/j.1523-5378.1996.tb00027.x] [PMID: 9398894]
[12]
Hassan IJ, Stark RM, Greenman J, Millar MR. Activities of beta-lactams and macrolides against Helicobacter pylori. Antimicrob Agents Chemother 1999; 43(6): 1387-92.
[http://dx.doi.org/10.1128/AAC.43.6.1387] [PMID: 10348758]
[13]
Hu JL, Yang J, Zhou YB, Li P, Han R, Fang DC. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol 2017; 23(5): 275-80.
[http://dx.doi.org/10.4103/sjg.SJG_91_17] [PMID: 28937021]
[14]
Malfertheiner P, Megraud F, O’Morain CA, et al. European Helicobacter Study Group. Management of Helicobacter pylori infection-The Maastricht IV/Florence Consensus Report. Gut 2012; 61(5): 646-64.
[http://dx.doi.org/10.1136/gutjnl-2012-302084] [PMID: 22491499]
[15]
Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors: The beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007; 17(13): 3585-94.
[http://dx.doi.org/10.1016/j.bmcl.2007.04.063] [PMID: 17482815]
[16]
Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest 2018; 48(1)
[http://dx.doi.org/10.1111/eci.12857] [PMID: 29144559]
[17]
Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol 2016; 111(12): 1736-42.
[http://dx.doi.org/10.1038/ajg.2016.443] [PMID: 27670603]
[18]
Öztürk H, Ozkirimli E, Özgür A. Classification of Beta-lactamases and penicillin binding proteins using ligand-centric network models. PLoS One 2015; 10(2): e0117874.
[http://dx.doi.org/10.1371/journal.pone.0117874] [PMID: 25689853]
[19]
White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53(Suppl. 1): i3-i20.
[http://dx.doi.org/10.1093/jac/dkh050] [PMID: 14726431]
[20]
Saudagar PS, Survase SA, Singhal RS. Clavulanic acid: A review. Biotechnol Adv 2008; 26(4): 335-51.
[http://dx.doi.org/10.1016/j.biotechadv.2008.03.002] [PMID: 18450406]
[21]
Farmer TH, Degnan BA, Payne DJ. Penetration of beta-lactamase inhibitors into the periplasm of gram-negative bacteria. FEMS Microbiol Lett 1999; 176(1): 11-5.
[PMID: 10418127]
[22]
Stokes DH, Wilkinson MJ, Tyler J, Slocombe B, Sutherland R. Bactericidal effects of amoxycillin/clavulanic acid against intracellular Legionella pneumophila in tissue culture studies. J Antimicrob Chemother 1989; 23(4): 547-56.
[http://dx.doi.org/10.1093/jac/23.4.547] [PMID: 2745260]
[23]
Buynak JD. Understanding the longevity of the beta-lactam antibiotics and of antibiotic/beta-lactamase inhibitor combinations. Biochem Pharmacol 2006; 71(7): 930-40.
[http://dx.doi.org/10.1016/j.bcp.2005.11.012] [PMID: 16359643]
[24]
Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39(6): 1211-33.
[http://dx.doi.org/10.1128/AAC.39.6.1211] [PMID: 7574506]
[25]
Bush K, Mobashery S. How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Adv Exp Med Biol 1998; 456: 71-98.
[http://dx.doi.org/10.1007/978-1-4615-4897-3_5] [PMID: 10549364]
[26]
Tseng YS, Wu DC, Chang CY, et al. Amoxicillin resistance with beta-lactamase production in Helicobacter pylori. Eur J Clin Invest 2009; 39(9): 807-12.
[http://dx.doi.org/10.1111/j.1365-2362.2009.02166.x] [PMID: 19614952]
[27]
Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit Rev Microbiol 2018; 44(3): 371-92.
[http://dx.doi.org/10.1080/1040841X.2017.1418285] [PMID: 29293032]
[28]
Howarth TT, Brown AG, King TJ. Clavulanic acid, a novel β-lactam isolated from Streptomyces clavuligerus; X-ray crystal structure analysis. J Chem Soc Chem Commun 1976; (7): 266b-7.
[http://dx.doi.org/10.1039/C3976000266B]
[29]
Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother 1998; 42(1): 1-17.
[http://dx.doi.org/10.1128/AAC.42.1.1] [PMID: 9449253]
[30]
Horii T, Kimura T, Sato-Kawamura K, Nada T, Shibayama K, Ohta M. beta-Lactamase inhibitors have antibacterial activities against Helicobacter pylori. J Infect Chemother 1999; 5(4): 206-7.
[http://dx.doi.org/10.1007/s101560050036] [PMID: 11810518]
[31]
Dore MP, Graham DY, Sepulveda AR, Realdi G, Osato MS. Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins. Antimicrob Agents Chemother 1999; 43(7): 1803-4.
[http://dx.doi.org/10.1128/AAC.43.7.1803] [PMID: 10390249]
[32]
Beale AS, Faulds E, Hurn SE, Tyler J, Slocombe B. Comparative activities of amoxycillin, amoxycillin/clavulanic acid and tetracycline against Chlamydia trachomatis in cell culture and in an experimental mouse pneumonitis. J Antimicrob Chemother 1991; 27(5): 627-38.
[http://dx.doi.org/10.1093/jac/27.5.627] [PMID: 1885420]
[33]
Bowie WR. In vitro activity of clavulanic acid, amoxicillin, and ticarcillin against Chlamydia trachomatis. Antimicrob Agents Chemother 1986; 29(4): 713-5.
[http://dx.doi.org/10.1128/AAC.29.4.713] [PMID: 3707116]
[34]
Cho H, Uehara T, Bernhardt TG. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell 2014; 159(6): 1300-11.
[http://dx.doi.org/10.1016/j.cell.2014.11.017] [PMID: 25480295]
[35]
Krishnamurthy P, Parlow MH, Schneider J, et al. Identification of a novel penicillin-binding protein from Helicobacter pylori. J Bacteriol 1999; 181(16): 5107-10.
[http://dx.doi.org/10.1128/JB.181.16.5107-5110.1999] [PMID: 10438788]
[36]
Bode G, Mauch F, Malfertheiner P. The coccoid forms of Helicobacter pylori. Criteria for their viability. Epidemiol Infect 1993; 111(3): 483-90.
[http://dx.doi.org/10.1017/S0950268800057216] [PMID: 8270008]
[37]
Loke MF, Ng CG, Vilashni Y, Lim J, Ho B. Understanding the dimorphic lifestyles of human gastric pathogen Helicobacter pylori using the SWATH-based proteomics approach. Sci Rep 2016; 6: 26784.
[http://dx.doi.org/10.1038/srep26784] [PMID: 27222005]
[38]
Faghri J, Poursina F, Moghim S, et al. Morphological and bactericidal effects of different antibiotics on Helicobacter pylori. Jundishapur J Microbiol 2014; 7(1): e8704.
[http://dx.doi.org/10.5812/jjm.8704] [PMID: 25147656]
[39]
Horii T, Mase K, Suzuki Y, et al. Antibacterial activities of beta-lactamase inhibitors associated with morphological changes of cell wall in Helicobacter pylori. Helicobacter 2002; 7(1): 39-45.
[http://dx.doi.org/10.1046/j.1523-5378.2002.00054.x] [PMID: 11886472]
[40]
Krzyżek P, Biernat MM, Gościniak G. Intensive formation of coccoid forms as a feature strongly associated with highly pathogenic Helicobacter pylori strains. Folia Microbiol (Praha) 2019; 64(3): 273-81.
[http://dx.doi.org/10.1007/s12223-018-0665-5] [PMID: 30449016]
[41]
Andersen LP, Rasmussen L. Helicobacter pylori-coccoid forms and biofilm formation. FEMS Immunol Med Microbiol 2009; 56(2): 112-5.
[http://dx.doi.org/10.1111/j.1574-695X.2009.00556.x] [PMID: 19453756]
[42]
Reshetnyak VI, Reshetnyak TM. Significance of dormant forms of Helicobacter pylori in ulcerogenesis. World J Gastroenterol 2017; 23(27): 4867-78.
[http://dx.doi.org/10.3748/wjg.v23.i27.4867] [PMID: 28785141]
[43]
DeLoney CR, Schiller NL. Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: Antibacterial activity and effects on bacterial morphology. Antimicrob Agents Chemother 1999; 43(11): 2702-9.
[http://dx.doi.org/10.1128/AAC.43.11.2702] [PMID: 10543750]
[44]
Van Craenenbroeck K, De Bosscher K, Vanden Berghe W, Vanhoenacker P, Haegeman G. Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Mol Cell Endocrinol 2005; 245(1-2): 10-22.
[http://dx.doi.org/10.1016/j.mce.2005.10.007] [PMID: 16310935]
[45]
Nieoullon A, Coquerel A. Dopamine: A key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003; 16(Suppl. 2): S3-9.
[http://dx.doi.org/10.1097/00019052-200312002-00002] [PMID: 15129844]
[46]
Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004; 10(13): 4349-56.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-0059] [PMID: 15240521]
[47]
Landeira-Fernandez J, Grijalva CV. Participation of the substantia nigra dopaminergic neurons in the occurrence of gastric mucosal erosions. Physiol Behav 2004; 81(1): 91-9.
[http://dx.doi.org/10.1016/j.physbeh.2004.01.004] [PMID: 15059688]
[48]
Rasheed N, Alghasham A. Central dopaminergic system and its implications in stress-mediated neurological disorders and gastric ulcers: Short review. Adv Pharmacol Sci 2012; 2012: 182671.
[http://dx.doi.org/10.1155/2012/182671] [PMID: 23008702]
[49]
Brzozowski T, Konturek PC, Konturek SJ, et al. Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Regul Pept 2004; 120(1-3): 39-51.
[http://dx.doi.org/10.1016/j.regpep.2004.02.010] [PMID: 15177919]
[50]
Szabo S, Neumeyer JL. Dopamine agonists and antagonists in duodenal ulcer disease Dopamine receptors. American Chemical Society 1983; Vol. 224: pp. 175-99.
[http://dx.doi.org/10.1021/bk-1983-0224.ch008]
[51]
Willems JL, Buylaert WA, Lefebvre RA, Bogaert MG. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 1985; 37(2): 165-216.
[PMID: 2996038]
[52]
Rasheed N, Ahmad A, Singh N, et al. Differential response of A 68930 and sulpiride in stress-induced gastric ulcers in rats. Eur J Pharmacol 2010; 643(1): 121-8.
[http://dx.doi.org/10.1016/j.ejphar.2010.06.032] [PMID: 20599913]
[53]
Kullmann R, Breull WR, Reinsberg J, Wassermann K, Konopatzki A. Dopamine produces vasodilation in specific regions and layers of the rabbit gastrointestinal tract. Life Sci 1983; 32(18): 2115-22.
[http://dx.doi.org/10.1016/0024-3205(83)90100-5] [PMID: 6843285]
[54]
Karzai W, Günnicker M, Scharbert G, Vorgrimler-Karzai UM, Priebe HJ. Effects of dopamine on oxygen consumption and gastric mucosal blood flow during cardiopulmonary bypass in humans. Br J Anaesth 1996; 77(5): 603-6.
[http://dx.doi.org/10.1093/bja/77.5.603] [PMID: 8957975]
[55]
Ozdemir V, Jamal MM, Osapay K, et al. Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: Revisiting the “brain-gut axis” hypothesis in ulcer pathogenesis. J Investig Med 2007; 55(6): 315-20.
[http://dx.doi.org/10.2310/6650.2007.00014] [PMID: 17963681]
[56]
Çamcı G, Oğuz S. Association between Parkinson’s disease and Helicobacter pylori. J Clin Neurol 2016; 12(2): 147-50.
[http://dx.doi.org/10.3988/jcn.2016.12.2.147] [PMID: 26932258]
[57]
Charlett A, Dobbs RJ, Dobbs SM, Weller C, Brady P, Peterson DW. Parkinsonism: Siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand 1999; 99(1): 26-35.
[http://dx.doi.org/10.1111/j.1600-0404.1999.tb00654.x] [PMID: 9925235]
[58]
Nakagawa H, Yamada M, Tokiyoshi K, Miyawaki Y, Kanayama T. Penetration of potassium clavulanate/ticarcillin sodium into cerebrospinal fluid in neurosurgical patients. Jpn J Antibiot 1994; 47(1): 93-101.
[PMID: 8114276]
[59]
Xiang Z, Censini S, Bayeli PF, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995; 63(1): 94-8.
[http://dx.doi.org/10.1128/IAI.63.1.94-98.1995] [PMID: 7806390]
[60]
Zu Y, Cassai ND, Sidhu GS. Light microscopic and ultrastructural evidence of in vivo phagocytosis of Helicobacter pylori by neutrophils. Ultrastruct Pathol 2000; 24(5): 319-23.
[http://dx.doi.org/10.1080/019131200750035049] [PMID: 11071570]
[61]
Allen L-AH. Phagocytosis and persistence of Helicobacter pylori. Cell Microbiol 2007; 9(4): 817-28.
[http://dx.doi.org/10.1111/j.1462-5822.2007.00906.x] [PMID: 17346311]
[62]
Suzuki T, Ina K, Nishiwaki T, et al. Differential roles of interleukin-1beta and interleukin-8 in neutrophil transendothelial migration in patients with Helicobacter pylori infection. Scand J Gastroenterol 2004; 39(4): 313-21.
[http://dx.doi.org/10.1080/00365520310008610] [PMID: 15125462]
[63]
Fu HW. Helicobacter pylori neutrophil-activating protein: From molecular pathogenesis to clinical applications. World J Gastroenterol 2014; 20(18): 5294-301.
[http://dx.doi.org/10.3748/wjg.v20.i18.5294] [PMID: 24833859]
[64]
Allen LA. Modulating phagocyte activation: The pros and cons of Helicobacter pylori virulence factors. J Exp Med 2000; 191(9): 1451-4.
[http://dx.doi.org/10.1084/jem.191.9.1451] [PMID: 10790419]
[65]
Schwartz JT, Allen LA. Role of urease in megasome formation and Helicobacter pylori survival in macrophages. J Leukoc Biol 2006; 79(6): 1214-25.
[http://dx.doi.org/10.1189/jlb.0106030] [PMID: 16543403]
[66]
Blaser MJ, Atherton JC. Helicobacter pylori persistence: Biology and disease. J Clin Invest 2004; 113(3): 321-33.
[http://dx.doi.org/10.1172/JCI20925] [PMID: 14755326]
[67]
Bongers S, Hellebrekers P, Leenen LPH, Koenderman L, Hietbrink F. Intracellular penetration and effects of antibiotics on Staphylococcus aureus inside human neutrophils: A comprehensive review. Antibiotics (Basel) 2019; 8(2): E54.
[http://dx.doi.org/10.3390/antibiotics8020054] [PMID: 31060222]
[68]
Bystrzycka W, Moskalik A, Sieczkowska S, Manda-Handzlik A, Demkow U, Ciepiela O. The effect of clindamycin and amoxicillin on Neutrophil Extracellular Trap (NET) release. Cent Eur J Immunol 2016; 41(1): 1-5.
[http://dx.doi.org/10.5114/ceji.2016.58811] [PMID: 27095915]
[69]
Reynaert M-L, Hochart-Behra A-C, Behra-Miellet J, et al. Comparison of the in vitro effects of amoxicillin and ampicillin on the polymorphonuclear neutrophil respiratory burst. J Antimicrob Chemother 2009; 63(3): 458-61.
[http://dx.doi.org/10.1093/jac/dkn545] [PMID: 19153080]
[70]
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar RD. Role of the normal gut microbiota. World J Gastroenterol 2015; 21(29): 8787-803.
[http://dx.doi.org/10.3748/wjg.v21.i29.8787] [PMID: 26269668]
[71]
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489(7415): 220-30.
[http://dx.doi.org/10.1038/nature11550] [PMID: 22972295]
[72]
Martin ME, Solnick JV. The gastric microbial community, Helicobacter pylori colonization, and disease. Gut Microbes 2014; 5(3): 345-50.
[http://dx.doi.org/10.4161/gmic.28573] [PMID: 24642475]
[73]
Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One 2008; 3(7): e2836-6.
[http://dx.doi.org/10.1371/journal.pone.0002836] [PMID: 18665274]
[74]
Song H-Y, Zhou L, Liu DY, Yao X-J, Li Y. What roles do probiotics play in the eradication of Helicobacter pylori? Current knowledge and ongoing research. Gastroenterol Res Pract 2018; 2018: 9379480.
[http://dx.doi.org/10.1155/2018/9379480] [PMID: 30410538]
[75]
Chenoll E, Casinos B, Bataller E, et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol 2011; 77(4): 1335-43.
[http://dx.doi.org/10.1128/AEM.01820-10] [PMID: 21169430]
[76]
Pinchuk IV, Bressollier P, Verneuil B, et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 2001; 45(11): 3156-61.
[http://dx.doi.org/10.1128/AAC.45.11.3156-3161.2001] [PMID: 11600371]
[77]
Sgouras D, Maragkoudakis P, Petraki K, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004; 70(1): 518-26.
[http://dx.doi.org/10.1128/AEM.70.1.518-526.2004] [PMID: 14711683]
[78]
Nam H, Ha M, Bae O, Lee Y. Effect of Weissella confusa strain PL9001 on the adherence and growth of Helicobacter pylori. Appl Environ Microbiol 2002; 68(9): 4642-5.
[http://dx.doi.org/10.1128/AEM.68.9.4642-4645.2002] [PMID: 12200324]
[79]
Khosravi Y, Dieye Y, Loke MF, Goh KL, Vadivelu J. Streptococcus mitis induces conversion of Helicobacter pylori to coccoid cells during co-culture in vitro. PLoS One 2014; 9(11): e112214.
[http://dx.doi.org/10.1371/journal.pone.0112214] [PMID: 25386948]
[80]
Johnson-Henry KC, Mitchell DJ, Avitzur Y, Galindo-Mata E, Jones NL, Sherman PM. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004; 49(7-8): 1095-102.
[http://dx.doi.org/10.1023/B:DDAS.0000037794.02040.c2] [PMID: 15387328]
[81]
Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000; 47(1): 79-87.
[http://dx.doi.org/10.1136/gut.47.1.79] [PMID: 10861268]
[82]
Alm RA, Trust TJ. Analysis of the genetic diversity of Helicobacter pylori: The tale of two genomes. J Mol Med (Berl) 1999; 77(12): 834-46.
[http://dx.doi.org/10.1007/s001099900067] [PMID: 10682319]
[83]
Salama N, Guillemin K, McDaniel TK, Sherlock G, Tompkins L, Falkow S. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc Natl Acad Sci USA 2000; 97(26): 14668-73.
[http://dx.doi.org/10.1073/pnas.97.26.14668] [PMID: 11121067]
[84]
Israel DA, Salama N, Krishna U, et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc Natl Acad Sci USA 2001; 98(25): 14625-30.
[http://dx.doi.org/10.1073/pnas.251551698] [PMID: 11724955]
[85]
Suerbaum S, Achtman M. Helicobacter pylori: Recombination, population structure and human migrations. Int J Med Microbiol 2004; 294(2-3): 133-9.
[http://dx.doi.org/10.1016/j.ijmm.2004.06.014] [PMID: 15493823]
[86]
Solnick JV, Hansen LM, Syvanen M. The major sigma factor (RpoD) from Helicobacter pylori and other gram-negative bacteria shows an enhanced rate of divergence. J Bacteriol 1997; 179(19): 6196-200.
[http://dx.doi.org/10.1128/JB.179.19.6196-6200.1997] [PMID: 9324272]
[87]
Fernandez-Gonzalez E, Backert S. DNA transfer in the gastric pathogen Helicobacter pylori. J Gastroenterol 2014; 49(4): 594-604.
[http://dx.doi.org/10.1007/s00535-014-0938-y] [PMID: 24515309]
[88]
Kersulyte D, Chalkauskas H, Berg DE. Emergence of recombinant strains of Helicobacter pylori during human infection. Mol Microbiol 1999; 31(1): 31-43.
[http://dx.doi.org/10.1046/j.1365-2958.1999.01140.x] [PMID: 9987107]
[89]
Oyarzabal OA, Rad R, Backert S. Conjugative transfer of chromosomally encoded antibiotic resistance from Helicobacter pylori to Campylobacter jejuni. J Clin Microbiol 2007; 45(2): 402-8.
[http://dx.doi.org/10.1128/JCM.01456-06] [PMID: 17135441]
[90]
Hofreuter D, Odenbreit S, Henke G, Haas R. Natural competence for DNA transformation in Helicobacter pylori: Identification and genetic characterization of the comB locus. Mol Microbiol 1998; 28(5): 1027-38.
[http://dx.doi.org/10.1046/j.1365-2958.1998.00879.x] [PMID: 9663688]
[91]
Kuipers EJ, Israel DA, Kusters JG, Blaser MJ. Evidence for a conjugation-like mechanism of DNA transfer in Helicobacter pylori. J Bacteriol 1998; 180(11): 2901-5.
[http://dx.doi.org/10.1128/JB.180.11.2901-2905.1998] [PMID: 9603879]
[92]
Backert S, Kwok T, König W. Conjugative plasmid DNA transfer in Helicobacter pylori mediated by chromosomally encoded relaxase and TraG-like proteins. Microbiology 2005; 151(Pt 11): 3493-503.
[http://dx.doi.org/10.1099/mic.0.28250-0] [PMID: 16272373]
[93]
Luo CH, Chiou PY, Yang CY, Lin NT. Genome, integration, and transduction of a novel temperate phage of Helicobacter pylori. J Virol 2012; 86(16): 8781-92.
[http://dx.doi.org/10.1128/JVI.00446-12] [PMID: 22696647]
[94]
Neuman H, Forsythe P, Uzan A, Avni O, Koren O. Antibiotics in early life: Dysbiosis and the damage done. FEMS Microbiol Rev 2018; 42(4): 489-99.
[http://dx.doi.org/10.1093/femsre/fuy018] [PMID: 29945240]
[95]
Thung I, Aramin H, Vavinskaya V, et al. Review article: The global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43(4): 514-33.
[http://dx.doi.org/10.1111/apt.13497] [PMID: 26694080]
[96]
Mégraud F H. pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004; 53(9): 1374-84.
[http://dx.doi.org/10.1136/gut.2003.022111] [PMID: 15306603]
[97]
Taneike I, Goshi S, Tamura Y, et al. Emergence of clarithromycin-resistant Helicobacter pylori (CRHP) with a high prevalence in children compared with their parents. Helicobacter 2002; 7(5): 297-305.
[http://dx.doi.org/10.1046/j.1523-5378.2002.00100.x] [PMID: 12390209]
[98]
Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017; 11: 2209-20.
[http://dx.doi.org/10.2147/DDDT.S136240] [PMID: 28814829]
[99]
Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 2000; 46(1): 121-3.
[http://dx.doi.org/10.1093/jac/46.1.121] [PMID: 10882700]
[100]
Crispino P, Iacopini F, Pica R, et al. Beta-lactamase inhibition with clavulanic acid supplementing standard amoxycillin-based triple therapy does not increase Helicobacter pylori eradication rate. Dig Liver Dis 2005; 37(11): 826-31.
[http://dx.doi.org/10.1016/j.dld.2005.07.010] [PMID: 16169304]
[101]
Ojetti V, Migneco A, Zocco MA, Nista EC, Gasbarrini G, Gasbarrini A. Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate. J Intern Med 2004; 255(1): 125-9.
[http://dx.doi.org/10.1046/j.0954-6820.2003.01239.x] [PMID: 14687248]
[102]
Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. BioMed Res Int 2014; 2014: 158520.
[PMID: 24995271]
[103]
Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design. Gut 2010; 59(5): 572-8.
[http://dx.doi.org/10.1136/gut.2009.198309] [PMID: 20427390]
[104]
Vcev A, Vceva A, Takac B, et al. Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. Acta medica Croatica 1998; 52(4-5): 209-14.
[105]
Dehghani SM, Erjaee A, Imanieh MH, Haghighat M. Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children. Dig Dis Sci 2009; 54(8): 1720-4.
[http://dx.doi.org/10.1007/s10620-008-0547-9] [PMID: 19005755]
[106]
Mirbagheri SA, Hasibi M, Abouzari M, Rashidi A. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: A comparative three-armed randomized clinical trial. World J Gastroenterol 2006; 12(30): 4888-91.
[http://dx.doi.org/10.3748/wjg.v12.i30.4888] [PMID: 16937475]
[107]
Wong BC, Lam SK, Wong WM, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004; 291(2): 187-94.
[http://dx.doi.org/10.1001/jama.291.2.187] [PMID: 14722144]
[108]
Zhang L, Shen L, Ma JL, et al. Eradication of H. pylori infection in a rural population: One-day quadruple therapy versus 7-day triple therapy. World J Gastroenterol 2006; 12(24): 3915-8.
[http://dx.doi.org/10.3748/wjg.v12.i24.3915] [PMID: 16804982]
[109]
Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis 2017; 30(5): 489-97.
[http://dx.doi.org/10.1097/QCO.0000000000000396] [PMID: 28704226]
[110]
Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8(4): 310-9.
[http://dx.doi.org/10.1046/j.1523-5378.2003.00158.x] [PMID: 12950604]
[111]
Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19(7): 538-41.
[http://dx.doi.org/10.1007/s100960000288] [PMID: 10968325]
[112]
Berry V, Jennings K, Woodnutt G. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother 1995; 39(8): 1859-61.
[http://dx.doi.org/10.1128/AAC.39.8.1859] [PMID: 7486933]
[113]
Labenz J, Stolte M, Blum AL, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: A study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37(1): 39-43.
[http://dx.doi.org/10.1136/gut.37.1.39] [PMID: 7672677]
[114]
Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin Drug Metab Toxicol 2010; 6(1): 29-41.
[http://dx.doi.org/10.1517/17425250903386251] [PMID: 19968574]
[115]
Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006; 24(2): 395-403.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02993.x] [PMID: 16842467]
[116]
Nishizawa T, Suzuki H, Maekawa T, et al. Dual therapy for third-line Helicobacter pylori eradication and urea breathe test prediction. World J Gastroenterol 2012; 18(21): 2735-8.
[http://dx.doi.org/10.3748/wjg.v18.i21.2735] [PMID: 22690086]
[117]
Murakami K, Furuta T, Ando T, et al. Japan GAST Study Group. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol 2013; 48(10): 1128-35.
[http://dx.doi.org/10.1007/s00535-012-0731-8] [PMID: 23307042]
[118]
Okimoto K, Arai M, Saito K, et al. Efficacy of levofloxacin based triple and high-dose PPI-amoxicillin dual eradication therapy for Helicobacter pylori after failures of first- and second-line therapies. Int Sch Res Notices 2014; 2014: 631501-1.
[http://dx.doi.org/10.1155/2014/631501] [PMID: 27379339]
[119]
Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015; 13(5): 895-905.
[http://dx.doi.org/10.1016/j.cgh.2014.10.036] [PMID: 25460556]
[120]
Garnock-Jones KP. Vonoprazan: First global approval. Drugs 2015; 75(4): 439-43.
[http://dx.doi.org/10.1007/s40265-015-0368-z] [PMID: 25744862]
[121]
Kim H-K, Park S-H, Cheung DY, et al. Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol 2010; 25(10): 1618-25.
[http://dx.doi.org/10.1111/j.1440-1746.2010.06408.x] [PMID: 20880169]
[122]
Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther 2018; 364(2): 275-86.
[http://dx.doi.org/10.1124/jpet.117.244202] [PMID: 29180359]
[123]
Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-A randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42(6): 719-30.
[http://dx.doi.org/10.1111/apt.13325] [PMID: 26193978]
[124]
Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep 2011; 13(6): 540-6.
[http://dx.doi.org/10.1007/s11894-011-0226-4] [PMID: 21993716]
[125]
Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39(1): 5-12.
[http://dx.doi.org/10.1093/jac/39.1.5] [PMID: 9044021]
[126]
Haginaka JUN, Nakagawa T, Uno T. Stability of clavulanic acid in aqueous solutions. Chem Pharm Bull (Tokyo) 1981; 29(11): 3334-41.
[http://dx.doi.org/10.1248/cpb.29.3334] [PMID: 7337933]
[127]
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20(3): 153-67.
[http://dx.doi.org/10.2133/dmpk.20.153] [PMID: 15988117]
[128]
Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016; 55(4): 409-18.
[http://dx.doi.org/10.1007/s40262-015-0326-7] [PMID: 26369775]
[129]
Lyu Q-J, Pu Q-H, Zhong X-F, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. BioMed Res Int 2019; 2019: 9781212-2.
[http://dx.doi.org/10.1155/2019/9781212] [PMID: 31211144]
[130]
Mori H, Suzuki H, Omata F, et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: A multicenter study with a large number of patients. Therap Adv Gastroenterol 2019; 12: 1756284819858511.
[http://dx.doi.org/10.1177/1756284819858511] [PMID: 31320930]
[131]
Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion 2019; 1-9.
[http://dx.doi.org/10.1159/000502287] [PMID: 31434101]
[132]
Graham DY, Dore MP. Update on the use of vonoprazan: A competitive acid blocker. Gastroenterology 2018; 154(3): 462-6.
[http://dx.doi.org/10.1053/j.gastro.2018.01.018] [PMID: 29337157]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy